Diagnosis of well-differentiated hepatocellular lesions: Role of immunohistochemistry and other ancillary techniques

Advances in Anatomic Pathology

Volumn 18, Issue 6, 2011, Pages 438-445

  Shafizadeh, Nafis ^a   Kakar, Sanjay ^b  

^a WOODLAND HILLS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FISH; focal nodular hyperplasia; hepatocellular adenoma; hepatocellular carcinoma; high grade dysplastic nodule; immunohistochemistry

Indexed keywords

AMYLOID; AMYLOID PROTEIN; BETA CATENIN; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CD34 ANTIGEN; CLUSTERIN; CYCLASE ASSOCIATED PROTEIN 2; CYTOKERATIN 7; ESTROGEN RECEPTOR; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; INTERLEUKIN 6 RECEPTOR; PROTEIN; RETICULIN; SERUM AMYLOID ASSOCIATED PROTEIN; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; BILE DUCT DISEASE; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CANCER MORPHOLOGY; CHROMOSOME 1Q; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HIGH GRADE DYSPLASTIC NODULE; LIVER NODULE; LIVER SINUSOID; MITOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCAR; SENSITIVITY AND SPECIFICITY; TELANGIECTASIA; TUMOR DIFFERENTIATION; UPREGULATION;

ADENOMA, LIVER CELL; ANTIGENS, CD34; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; FOCAL NODULAR HYPERPLASIA; GENE EXPRESSION PROFILING; GLUTAMATE-AMMONIA LIGASE; GLYPICANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; LIVER CIRRHOSIS;

EID: 80054694374     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318234abb4     Document Type: Review

References (64)

1. Fukukura Y, Nakashima O, Kusaba A, et al. Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. J Hepatol. 1998;29:470-475. (Pubitemid 28396666)
2. Paradis V, Laurent A, Flejou JF, et al. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology. 1997;26:891-895. (Pubitemid 27413654)
3. Wanless IR, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology. 1985;5:1194-1200. (Pubitemid 16222291)
4. Mortele KJ, Praet M, Van VH, et al. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologicpathologic correlation. AJR Am J Roentgenol. 2000;175:687-692.
5. Bioulac-Sage P, Balabaud C, Bedossa P, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46:521-527. (Pubitemid 46201719)
6. Bioulac-Sage P, Laumonier H, Laurent C, et al. Hepatocellular adenoma: what is new in 2008. Hepatol Int. 2008;2:316-321.
7. Bioulac-Sage P, Laumonier H, Sa CA, et al. Hepatocellular adenomas. Liver Int. 2009;29:142.
8. Wanless IR, Belgiorno J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit. 1: morphology and inhibition of fibrogenesis by dipyridamole. Hepatology. 1996;24:855-864. (Pubitemid 26334285)
9. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology. 2004;126:1323-1329. (Pubitemid 38559002)
10. Gebhardt R, Baldysiak-Figiel A, Krugel V, et al. Hepatocellular expression of glutamine synthetase: an indicator of morphogen actions as master regulators of zonation in adult liver. Prog Histochem Cytochem. 2007;41:201-266. (Pubitemid 46412421)
11. Bioulac-Sage P, Laumonier H, Rullier A, et al. Overexpression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int. 2009;29:459-465.
12. Joseph NM, Jain D, Wu T, et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and telangiectatic hepatic adenoma (abstract). Mod Path. 2011;24:364A.
13. Paradis V. How to classify a benign liver cell tumor in 2008? Gastroenterol Clin Biol. 2008;32:294-295.
14. Ahmad I, Iyer A, Marginean CE, et al. Diagnostic use of cytokeratins, CD34, and neuronal cell adhesion molecule staining in focal nodular hyperplasia and hepatic adenoma. Hum Pathol. 2009;40:726-734.
15. Iyer A, Robert ME, Bifulco CB, et al. Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol. 2008;39:1370-1377.
16. Kakar S, Chen X, Ho C, et al. Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms. Histopathology. 2009;55:197-205.
17. Capurro M, Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res. 2005;65:372-373. (Pubitemid 40070831)
18. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97. (Pubitemid 36799110)
19. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. (Pubitemid 40994223)
20. Komori H, Beppu T, Baba H, et al. Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma. Nihon Rinsho. 2010;68(Suppl 7):833-836.
21. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. Cancer. 2009;117:271-278.
22. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. Bio Drugs. 2005;19:71-77. (Pubitemid 40559473)
23. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612-6621. (Pubitemid 39346558)
24. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230.
25. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasialike nodules. Am J Surg Pathol. 2006;30:1405-1411. (Pubitemid 44655475)
26. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011-1018.
27. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441. (Pubitemid 44739946)
28. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598. (Pubitemid 41670658)
29. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558-564. (Pubitemid 32234802)
30. Fan Z, van de Rijn M, Montgomery K, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol. 2003;16:137-144. (Pubitemid 36245745)
31. Yan BC, Gong C, Song J, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147-1154.
32. Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748. (Pubitemid 47436120)
33. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotypephenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
34. Rebouissou S, Amessou M, Couchy G, et al. Frequent inframe somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457:200-204.
35. Bioulac-Sage P, Blanc JF, Rebouissou S, et al. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol. 2007;13:2649-2654. (Pubitemid 46958719)
36. Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155:1795-1801.
37. Evason K, Grenert JP, Ferrell L, et al. Immunohistochemical classification of hepatic adenomas and atypical hepatocellular neoplasms: correlation with clinicopathologic characteristics and chromosomal abnormalities (abstract). Mod Path. 2010;23:354A.
38. Dhillon AP, Colombari R, Savage K, et al. An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver. 1992;12:311-318.
39. Kimura H, Nakajima T, Kagawa K, et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver. 1998;18:14-19. (Pubitemid 28127752)
40. Balsara BR, Pei J, De RA, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1-24.1. Genes Chromosomes Cancer. 2001;30:245-253. (Pubitemid 32126200)
41. Poon TC, Wong N, Lai PB, et al. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology. 2006;131:1262-1270. (Pubitemid 44515104)
42. Nolte M, Werner M, Nasarek A, et al. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol. 1998;51:47-51. (Pubitemid 28122586)
43. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn. 2001;3:68-73. (Pubitemid 32440245)
44. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol. 2001;193:476-482. (Pubitemid 32266816)
45. Wilkens L, Bredt M, Flemming P, et al. Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) in the diagnosis of hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2002;9:304-311. (Pubitemid 34993678)
46. Chen ZM, Crone KG, Watson MA, et al. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol. 2005;29:1600-1608.
47. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
48. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
49. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
50. Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology. 2005;42:14-16. (Pubitemid 40911304)
51. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658-64.
52. Desmet VJ. East-West pathology agreement on precancerous liver lesions and early hepatocellular carcinoma. Hepatology. 2009;49:355-357.
53. Roncalli M, Borzio M, Di TL. Hepatocellular dysplastic nodules. Hepatol Res. 2007;37(Suppl 2):S125-S134.
54. Wanless IR. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology. 1995;22:983-993.
55. Park YN, Kojiro M, Di TL, et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer. 2007;109:915-923. (Pubitemid 46333533)
56. Park YN, Yang CP, Fernandez GJ, et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol. 1998;22:656-662. (Pubitemid 28280267)
57. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37:198-207. (Pubitemid 36042161)
58. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725-734. (Pubitemid 46450624)
59. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009;50:746-754.
60. Lim SO, Park SG, Yoo JH, et al. Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol. 2005;11:2072-2079. (Pubitemid 40542649)
61. Sakamoto M, Mori T, Masugi Y, et al. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(Suppl 1):42-45. (Pubitemid 351821841)
62. Abdul-Al HM, Makhlouf HR, Wang G, et al. Glypican-3 expression in benign liver tissue with active hepatitis C: implications for the diagnosis of hepatocellular carcinoma. Hum Pathol. 2008;39:209-212.
63. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology. 2006;131:1758-1767. (Pubitemid 46001394)
64. Paradis V, Bieche I, Dargere D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RTPCR approach: determination of a molecular diagnostic index. Am J Pathol. 2003;163:733-741. (Pubitemid 36909434)